Blue Water Vaccines, Inc.
We are a biotechnology company focused on the research and development of transformational vaccines to prevent infectious diseases worldwide. Our versatile vaccine platform has unique molecular properties that enables delivery of various antigens, which can be utilized to develop singular or multi-targeted vaccines. Our lead influenza (flu) vaccine program uses proprietary technology to identify specific epitopes, or proteins, with cross-reactive properties that enables the potential development of a universal flu vaccine. We are focused on developing novel vaccines that induce durable and long-term immunity. We believe that our pipeline and vaccine platform are synergistic for developing next generation preventive vaccines to improve both health outcomes and quality of life globally.
Our pipeline includes novel vaccine candidates exclusively licensed from renowned research institutions. We seek to develop vaccines that provide long-lasting immunity to harmful viral and bacterial pathogens that cause infections in patient populations with high unmet needs. Our exclusive license agreements include patented influenza epitopes of limited variability, or ELV, identified through a proprietary computational research and discovery process, discovered by Dr. Sunetra Gupta and her team at the University of Oxford. Our collaborators are pioneers in vaccine discovery and development. We are exploring the development of these influenza ELV’s utilizing our Norovirus shell and protrusion (S&P) nanoparticle vaccine platform licensed from Cincinnati Children’s Hospital Medical Center, or CHMC. We are also utilizing our platform to develop a vaccine for the prevention of gastroenteritis cause by both norovirus and rotavirus. Our exclusively licensed S. pneumoniae vaccine candidate is from St. Jude Children’s Research Hospital. The vaccine is designed to prevent harmful middle-ear infections in children and is being developed for intranasal delivery, well suited for pediatric patients. We leverage the expertise of our collaborators to pursue the discovery and development of vaccines for these diseases, which are high unmet needs globally.
(Note: Blue Water Vaccines, Inc. priced its IPO on Feb. 17, 2022, at $9 – the mid-point of its $8-to-$10 range – and sold 2.22 million shares, the same number of shares in the prospectus, to raise $In an S-1/A filing dated Feb. 8, 2022, Blue Water Vaccines changed the sole book-runner on its IPO to Boustead Securities from its previous underwriter, Maxim Group LLC. Blue Water Vaccines filed its S-1 on Oct. 8, 2021.)
|Address||201 E. Fifth Street, Suite 1900 Cincinnati, Ohio 45202|
|Phone Number||(513) 620-4101|
|View Prospectus:||Blue Water Vaccines, Inc.|
|Revenues||$0 mil (last 12 months)|
|Net Income||$-2.61 mil (last 12 months)|
|Price range||$9.00 - $9.00|
|Est. $ Volume||$20.0 mil|
|Manager / Joint Managers||Boustead Securities|
|Expected To Trade:||2/18/2022|
|Quiet Period Expiration Date:||Available only to Subscribers|
|Lock-Up Period Expiration Date:||Available only to Subscribers|
|SCOOP Rating||Available only to Subscribers|
|Rating Change||Available only to Subscribers|